The observational analysis compared sodium-glucose co-transporter-2 (SGLT2) inhibitors with other glucose-lowering drugs in patients with type 2 diabetes in Denmark, Norway, and Sweden.
Results from the Diabetes Prevention Program Outcomes Study also showed that metformin was cost-effective compared to placebo for patients at high risk of diabetes.
Patients with type 1 diabetes taking dapagliflozin for 24 weeks had lower HbA1c level, body weight, and insulin dose than those on placebo, according to the industry-funded study.
Canagliflozin may have lower risk of cardiovascular events compared to placebo, industry-funded study finds
The study found a higher risk of amputation of toes, feet, or legs with canagliflozin than with placebo, with most amputations occurring at the toe or metatarsal.
Among both men and women in Finland, height was inversely associated with two-hour plasma glucose concentration, except among patients with a body-mass index of 35 kg/m2 or more.
The industry-funded study used international data to compare rates of heart failure hospitalization and mortality in patients on sodium glucose cotransporter-2 (SGLT2) inhibitors or other glucose-lowering drugs.
health status, comorbid conditions, or glycemic control and highlight the fact that potential overtreatment of diabetes is a widespread issue.
In addition to approved drugs duloxetine, pregabalin, and tapentadol, some benefits were found with venlafaxine, oxcarbazepine, tricyclic antidepressants, tramadol, and botulinum toxin.
Screening tool identifies high-risk drivers with type 1 diabetes and website helps to avoid future accidents
Significant independent predictors of risk for driving mishaps included annual driving distance and presence of peripheral neuropathy. Researchers developed an 11-item questionnaire to further refine risk prediction.
Compared to those with type 1 diabetes, participants with type 2 had a significantly higher age-adjusted prevalence of diabetic kidney disease, retinopathy, peripheral, arterial stiffness, and hypertension by age 21.